Small Business Innovation Research (SBIR) Program Phase I Allocation of Rights in Intellectual Property and Rights to Carry Out Follow-on Research, Development, or CommercializationSbir Phase I Agreement • February 13th, 2017 • Shuttle Pharmaceuticals, Inc. • Pharmaceutical preparations
This SBIR Phase I agreement (“Agreement”) between Shuttle Pharmaceuticals, Inc., a small business concern organized as corporation under the laws of Maryland having a principal place of business at One Research Court, Suite 450, Rockville, MD 20850, (“SBC”) and Georgetown University, a nonprofit institution of higher education organized as a non-stock corporation under federal charter and whose principal place of business is situated at 37th and O Streets, N.W., Washington, D.C., U.S.A. (hereinafter called “Georgetown”) is entered into for the purpose of allocating between the parties certain rights relating to an SBIR project to be carried out by SBC and Georgetown (hereinafter individually referred to as Party or collectively as “Parties”) under an SBIR funding agreement awarded by the National Institutes of Health (“AGENCY”) to SBC, (HHSN261600038C) to fund a proposal entitled, “Cell and Animal Based Models to Advance Health Disparity Research.”
PNC BANK, NATIONAL ASSOCIATION Investor Deposit Escrow AgreementDeposit Escrow Agreement • February 13th, 2017 • Shuttle Pharmaceuticals, Inc. • Pharmaceutical preparations
This Investor Deposit Escrow Agreement (this “Agreement”), dated as of ________ __, 2017, is by and between Shuttle Pharmaceuticals, Inc., a Maryland corporation, having its principal place of business at 1 Research Court, Suite 450, Rockville, Maryland 20850 (the “Company”) and PNC Bank, National Association, a national banking association with its principal place of business at _________________________________________ (the "Escrow Agent"). The Company and the Escrow Agent are sometimes referred to herein individually, as a “Party” and collectively, as the “Parties.”
SHUTTLE PHARMACEUTICALS, LLC AND POLA PHARMA INC. EXCLUSIVE OPTION AGREEMENTExclusive Option Agreement • February 13th, 2017 • Shuttle Pharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
This Agreement, executed on this 4 th day of July , 2016 (“Effective Date”), by and between, POLA PHARMA INC., a pharmaceutical company organized and existing under the laws of Japan, with its principal office located in 8-9-5 Nishigotanda Shinagawa-ku, Tokyo 141-0031, JAPAN, (hereinafter referred to as “POLA”) and Shuttle Pharmaceuticals, LLC, a Maryland (USA) limited liability company having its principal place of business located at One Research Court, Ste. 450, Rockville, Maryland 20850 (“OPTIONEE”), defines the terms of the confidential relationship between the aforementioned parties (hereafter referred to as the “Parties” collectively or “Party” individually).
Subaward AgreementSubaward Agreement • February 13th, 2017 • Shuttle Pharmaceuticals, Inc. • Pharmaceutical preparations
SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM RESEARCH AGREEMENT AND SUBCONTRACT BETWEEN GEORGETOWN UNIVERSITY AND SHUTTLE PHARMACEUTICALS, LLC. PURSUANT TO AWARD NUMBER HHSN261201600027C - NCI CONTROL NUMBER:N43CO-2016-00027 ("Predictive...Research Agreement • February 13th, 2017 • Shuttle Pharmaceuticals, Inc. • Pharmaceutical preparations • District of Columbia
In consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, and intending to be legally bound, the parties expressly agree to the terms and conditions contained in this Agreement.
SUBSCRIPTION AGREEMENTSubscription Agreement • February 13th, 2017 • Shuttle Pharmaceuticals, Inc. • Pharmaceutical preparations
The undersigned (the "Subscriber"), desires to become a holder of common shares (the "Shares") of Shuttle Pharmaceuticals, Inc., a corporation organized under the laws of the state of Maryland, having its principal place of business located at1 Research Court, Suite 450, Rockville, Maryland 20850 (the "Company").
